|
Dr. Reddy’s Pipeline to Focus on Complex, Limited-Competition Generics
Dr. Reddy’s plans to key in on more complex generics such as injectables, particularly in the U.S. market, to help insulate its products from fierce competition.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives